Document is current
Any future updates will be listed below
-
Authors
Ishida, Yuriko
Ikeda, Satoshi https://orcid.org/0000-0001-5203-7911
Harada, Toshiyuki
Sakakibara-Konishi, Jun
Yokoo, Keiki
Kikuchi, Hajime
Iwasawa, Tae
Misumi, Toshihiro
Konno, Satoshi
Ogura, Takashi
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 23 February 2025
First Online: 8 March 2025
Declarations
:
: Satoshi Ikeda received honoraria from AstraZeneca, Bristol Myers Squibb, Ono, Taiho, Chugai, Boehringer Ingelheim, Eli Lilly, Takeda, Pfizer, MSD, Amgen, and Novartis; research funding from AstraZeneca and Chugai; and took on a consulting or advisory roles for AstraZeneca, Chugai and Daiichi Sankyo. Yuriko Ishida, Toshiyuki Harada, Jun Sakakibara-Konishi, and Hajime Kikuchi, have no conflicts of interest to declare. Keiki Yokoo received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., Merck Serono, MSD K.K., NIPPON KAYAKU, Takeda Pharmaceutical Co. Ltd. Toshihiro Misumi received honoraria from AstraZeneca, Chugai, and Miyarisan. Tae Iwasawa received honoraria from Astellas Pharma, Toray Industries, Chugai, Eisai, Japanese Boehringer Ingelheim, Shionogi & Co., Ltd; and participated on a Data Safety Monitoring Board or Advisory Board to Bristol Myers Squibb, Japanese Boehringer Ingelheim, Taiho Pharmaceutical Co., Ltd. Satoshi Konno received research funding from Chugai Pharmaceutical. Takashi Ogura received honoraria from Astellas Pharma, Chugai, Eisai, Japanese Boehringer Ingelheim, Shionogi & Co., Ltd., Toray industries; and participated on a Data Safety Monitoring Board or Advisory Board to Bristol Myers Squibb, Japanese Boehringer Ingelheim, Taiho Pharmaceutical Co., Ltd.
